Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mEphA4-Fc
- Development stage
- Unknown
- Lead developer
- NuNerve
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
mEphA4-Fc (also known as NUN-004) is a recombinant fusion protein developed by NuNerve Pty. Ltd. for the treatment of amyotrophic lateral sclerosis (ALS). It consists of a modified version of the EphA4 receptor extracellular domain fused to an Fc fragment, engineered to have an extended half-life compared to the native EphA4-Fc construct. The drug acts as an antagonist of the EphA4 (Ephrin type-A receptor 4), a receptor tyrosine kinase that has been identified as a genetic modifier of ALS progression. By inhibiting EphA4 signaling, which is thought to contribute to motor neuron degeneration and limit axonal regeneration, mEphA4-Fc aims to slow the progression of the disease. It has been evaluated in a Phase I/Ib first-in-human study to assess safety, tolerability, and pharmacokinetics in healthy volunteers and patients with ALS.
- Other names
- modified EphA4-Fc
02
Targets
FcγR/C1q (Fc gamma receptors and complement component C1q)EFNA/EFNB (Ephrin ligand)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on mEphA4-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mEphA4-Fc.